# Moderna

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/moderna/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| OpenAlex ID | https://openalex.org/F4320319071 |
| ROR ID | https://ror.org/01xm4wg91 |
| Works | 5,961 |

## Funder papers

- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial](https://scholariq.org/papers/effect-of-empagliflozin-on-heart-failure-outcomes-after-acute-myocardial/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction](https://scholariq.org/papers/secondary-analysis-of-the-empact-mi-trial-reveals-cardiovascular-kidney-efficacy/)
- [ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors](https://scholariq.org/papers/araf-amplification-in-small-cell-lung-cancer-transformed-tumors-following/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.